{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T11:43:02Z","timestamp":1792669382469,"version":"4.5.0"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T00:00:00Z","timestamp":1574899200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000862","name":"Doris Duke Charitable Foundation","doi-asserted-by":"publisher","award":["2015008"],"award-info":[{"award-number":["2015008"]}],"id":[{"id":"10.13039\/100000862","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007138","name":"Ryan Licht Sang Bipolar Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007138","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Human postmortem studies suggest a major role for abnormalities in GABAergic interneurons in the prefrontal cortex in schizophrenia. Cortical interneurons differentiated from induced pluripotent stem cells (iPSCs) of schizophrenia subjects showed significantly lower levels of glutamate decarboxylase 67 (GAD67), replicating findings from multiple postmortem studies, as well as reduced levels of synaptic proteins gehpyrin and NLGN2. Co-cultures of the interneurons with excitatory cortical pyramidal neurons from schizophrenia iPSCs showed reduced synaptic puncta density and lower action potential frequency. NLGN2 overexpression in schizophrenia neurons rescued synaptic puncta deficits while NLGN2 knockdown in healthy neurons resulted in reduced synaptic puncta density. Schizophrenia interneurons also had significantly smaller nuclear area, suggesting an innate oxidative stressed state. The antioxidant <jats:italic>N<\/jats:italic>-acetylcysteine increased the nuclear area in schizophrenia interneurons, increased NLGN2 expression and rescued synaptic deficits. These results implicate specific deficiencies in the synaptic machinery in cortical interneurons as critical regulators of synaptic connections in schizophrenia and point to a nexus between oxidative stress and NLGN2 expression in mediating synaptic deficits in schizophrenia.<\/jats:p>","DOI":"10.1038\/s41398-019-0660-x","type":"journal-article","created":{"date-parts":[[2019,11,28]],"date-time":"2019-11-28T12:04:00Z","timestamp":1574942640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":65,"title":["Synaptic deficits in iPSC-derived cortical interneurons in schizophrenia are mediated by NLGN2 and rescued by N-acetylcysteine"],"prefix":"10.1038","volume":"9","author":[{"given":"Annie","family":"Kathuria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara","family":"Lopez-Lengowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bradley","family":"Watmuff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"McPhie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce M.","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakesh","family":"Karmacharya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,11,28]]},"reference":[{"key":"660_CR1","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(04)16458-1","volume":"363","author":"KT Mueser","year":"2004","unstructured":"Mueser, K. T. & McGurk, S. R. Schizophrenia. Lancet 363, 2063\u20132072 (2004).","journal-title":"Lancet"},{"key":"660_CR2","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/schbul\/23.2.287","volume":"23","author":"M Harrow","year":"1997","unstructured":"Harrow, M., Sands, J. R., Silverstein, M. L. & Goldberg, J. F. Course and outcome for schizophrenia versus other psychotic patients: a longitudinal study. Schizophr. Bull. 23, 287\u2013303 (1997).","journal-title":"Schizophr. Bull."},{"key":"660_CR3","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2015.115","volume":"5","author":"LD Selemon","year":"2015","unstructured":"Selemon, L. D. & Zecevic, N. Schizophrenia: a tale of two critical periods for prefrontal cortical development. Transl. Psychiatry 5, e623 (2015).","journal-title":"Transl. Psychiatry"},{"key":"660_CR4","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1001\/archpsyc.64.10.1123","volume":"64","author":"S Saha","year":"2007","unstructured":"Saha, S., Chant, D. & McGrath, J. A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Arch. Gen. Psychiatry 64, 1123\u20131131 (2007).","journal-title":"Arch. Gen. Psychiatry"},{"key":"660_CR5","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1007\/s004060070002","volume":"250","author":"A Jablensky","year":"2000","unstructured":"Jablensky, A. Epidemiology of schizophrenia: the global burden of disease and disability. Eur. Arch. Psychiatry Clin. Neurosci. 250, 274\u2013285 (2000).","journal-title":"Eur. Arch. Psychiatry Clin. Neurosci."},{"key":"660_CR6","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.euroneuro.2005.04.009","volume":"15","author":"W R\u00f6ssler","year":"2005","unstructured":"R\u00f6ssler, W., Salize, H. J., van Os, J. & Riecher-R\u00f6ssler, A. Size of burden of schizophrenia and psychotic disorders. Eur. Neuropsychopharmacol. 15, 399\u2013409 (2005).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"660_CR7","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.euroneuro.2015.01.015","volume":"25","author":"MJ Millan","year":"2015","unstructured":"Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A. & \u00d6gren, S. O. 60 years of advances in neuropsychopharmacology for improving brain health, renewed hope for progress. Eur. Neuropsychopharmacol. 25, 591\u2013598 (2015).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"660_CR8","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1016\/j.euroneuro.2015.01.016","volume":"25","author":"MJ Millan","year":"2015","unstructured":"Millan, M. J., Goodwin, G. M., Meyer-Lindenberg, A. & Ove \u00d6gren, S. Learning from the past and looking to the future: emerging perspectives for improving the treatment of psychiatric disorders. Eur. Neuropsychopharmacol. 25, 599\u2013656 (2015).","journal-title":"Eur. Neuropsychopharmacol."},{"key":"660_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-017-0071-9","volume":"8","author":"JP Kesby","year":"2018","unstructured":"Kesby, J. P., Eyles, D. W., McGrath, J. J. & Scott, J. G. Dopamine, psychosis and schizophrenia: the widening gap between basic and clinical neuroscience. Transl. Psychiatry 8, 30 (2018).","journal-title":"Transl. Psychiatry"},{"key":"660_CR10","doi-asserted-by":"publisher","first-page":"146","DOI":"10.2174\/1566524015666150303003028","volume":"15","author":"R Gao","year":"2015","unstructured":"Gao, R. & Penzes, P. Common mechanisms of excitatory and inhibitory imbalance in schizophrenia and autism spectrum disorders. Curr. Mol. Med. 15, 146\u201367. (2015).","journal-title":"Curr. Mol. Med."},{"key":"660_CR11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.12688\/f1000research.12155.1","volume":"7","author":"M Selten","year":"2018","unstructured":"Selten, M., van Bokhoven, H. & Nadif Kasri, N. Inhibitory control of the excitatory\/inhibitory balance in psychiatric disorders. F1000Res 7, 23 (2018).","journal-title":"F1000Res"},{"key":"660_CR12","doi-asserted-by":"publisher","first-page":"6","DOI":"10.3389\/neuro.02.006.2008","volume":"1","author":"C Kehrer","year":"2008","unstructured":"Kehrer, C., Maziashvili, N., Dugladze, T. & Gloveli, T. Altered excitatory-inhibitory balance in the NMDA-hypofunction model of schizophrenia. Front. Mol. Neurosci. 1, 6 (2008).","journal-title":"Front. Mol. Neurosci."},{"key":"660_CR13","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.nbd.2012.11.013","volume":"53","author":"M Inan","year":"2013","unstructured":"Inan, M., Petros, T. J. & Anderson, S. A. Losing your inhibition: linking cortical GABAergic interneurons to schizophrenia. Neurobiol. Dis. 53, 36\u201348 (2013).","journal-title":"Neurobiol. Dis."},{"key":"660_CR14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0893-133X(01)00225-1","volume":"25","author":"FM Benes","year":"2001","unstructured":"Benes, F. M. & Berretta, S. GABAergic interneurons: implications for understanding schizophrenia and bipolar disorder. Neuropsychopharmacology 25, 1\u201327 (2001).","journal-title":"Neuropsychopharmacology"},{"key":"660_CR15","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.tins.2011.10.004","volume":"35","author":"DA Lewis","year":"2012","unstructured":"Lewis, D. A., Curley, A. A., Glausier, J. R. & Volk, D. W. Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci. 35, 57\u201367 (2012).","journal-title":"Trends Neurosci."},{"key":"660_CR16","doi-asserted-by":"publisher","first-page":"37","DOI":"10.3389\/fncir.2018.00037","volume":"12","author":"BR Ferguson","year":"2018","unstructured":"Ferguson, B. R. & Gao, W. J. PV interneurons: critical regulators of E\/I balance for prefrontal cortex-dependent behavior and psychiatric disorders. Front Neural Circuits 12, 37 (2018).","journal-title":"Front Neural Circuits"},{"key":"660_CR17","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.ymthe.2018.12.009","volume":"27","author":"L Warren","year":"2019","unstructured":"Warren, L. & Lin, C. mRNA-based genetic reprogramming. Mol. Ther. 27, 729\u201334. (2019).","journal-title":"Mol. Ther."},{"key":"660_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/1756-6606-7-22","volume":"7","author":"H Okano","year":"2014","unstructured":"Okano, H. & Yamanaka, S. iPS cell technologies: significance and applications to CNS regeneration and disease. Mol. Brain 7, 22 (2014).","journal-title":"Mol. Brain"},{"key":"660_CR19","doi-asserted-by":"publisher","first-page":"1670","DOI":"10.1038\/nprot.2013.106","volume":"8","author":"Y Liu","year":"2013","unstructured":"Liu, Y. et al. Directed differentiation of forebrain GABA interneurons from human pluripotent stem cells. Nat. Protoc. 8, 1670\u20131679 (2013).","journal-title":"Nat. Protoc."},{"key":"660_CR20","doi-asserted-by":"publisher","first-page":"6315","DOI":"10.1523\/JNEUROSCI.23-15-06315.2003","volume":"23","author":"T Hashimoto","year":"2003","unstructured":"Hashimoto, T. et al. Gene expression deficits in a subclass of GABA neurons in the prefrontal cortex of subjects with schizophrenia. J. Neurosci. 23, 6315\u20136326 (2003).","journal-title":"J. Neurosci."},{"key":"660_CR21","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1001\/archpsyc.1995.03950160008002","volume":"52","author":"S Akbarian","year":"1995","unstructured":"Akbarian, S. et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch. Gen. Psychiatry 52, 258\u2013266 (1995).","journal-title":"Arch. Gen. Psychiatry"},{"key":"660_CR22","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1001\/archpsyc.57.3.237","volume":"57","author":"DW Volk","year":"2000","unstructured":"Volk, D. W., Austin, M. C., Pierri, J. N., Sampson, A. R. & Lewis, D. A. Decreased glutamic acid decarboxylase67 messenger RNA expression in a subset of prefrontal cortical gamma-aminobutyric acid neurons in subjects with schizophrenia. Arch. Gen. Psychiatry 57, 237\u2013245 (2000).","journal-title":"Arch. Gen. Psychiatry"},{"key":"660_CR23","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1093\/schbul\/sbv065","volume":"41","author":"KQ Do","year":"2015","unstructured":"Do, K. Q., Cuenod, M. & Hensch, T. K. Targeting oxidative stress and aberrant critical period plasticity in the developmental trajectory to schizophrenia. Schizophr. Bull. 41, 835\u2013846 (2015).","journal-title":"Schizophr. Bull."},{"key":"660_CR24","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1111\/j.1460-9568.2012.08130.x","volume":"35","author":"P O\u2019Donnell","year":"2012","unstructured":"O\u2019Donnell, P. Cortical interneurons, immune factors and oxidative stress as early targets for schizophrenia. Eur. J. Neurosci. 35, 1866\u20131870 (2012).","journal-title":"Eur. J. Neurosci."},{"key":"660_CR25","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.schres.2014.06.021","volume":"176","author":"P Steullet","year":"2016","unstructured":"Steullet, P. et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: a \u201ccentral hub\u201d in schizophrenia pathophysiology? Schizophr. Res. 176, 41\u201351 (2016).","journal-title":"Schizophr. Res."},{"key":"660_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2017.138","volume":"7","author":"DA Maas","year":"2017","unstructured":"Maas, D. A., Vall\u00e8s, A. & Martens, G. J. M. Oxidative stress, prefrontal cortex hypomyelination and cognitive symptoms in schizophrenia. Transl. Psychiatry 7, e1171 (2017).","journal-title":"Transl. Psychiatry"},{"key":"660_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/schbul\/sbw129","volume":"43","author":"SY Kim","year":"2017","unstructured":"Kim, S. Y. et al. Redox dysregulation in schizophrenia revealed by in vivo NAD+\/NADH measurement. Schizophr. Bull. 43, 197\u2013204 (2017).","journal-title":"Schizophr. Bull."},{"key":"660_CR28","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1093\/schbul\/sbs052","volume":"38","author":"EM Sullivan","year":"2012","unstructured":"Sullivan, E. M. & O\u2019Donnell, P. Inhibitory interneurons, oxidative stress, and schizophrenia. Schizophr. Bull. 38, 373\u2013376 (2012).","journal-title":"Schizophr. Bull."},{"key":"660_CR29","doi-asserted-by":"publisher","first-page":"411","DOI":"10.4161\/nucl.21674","volume":"3","author":"A Barascu","year":"2012","unstructured":"Barascu, A. et al. Oxydative stress alters nuclear shape through lamins dysregulation: a route to senescence. Nucleus 3, 411\u2013417 (2012).","journal-title":"Nucleus"},{"key":"660_CR30","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1176\/appi.ajp.2011.11010052","volume":"168","author":"AA Curley","year":"2011","unstructured":"Curley, A. A. et al. Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Am. J. Psychiatry 168, 921\u2013929 (2011).","journal-title":"Am. J. Psychiatry"},{"key":"660_CR31","doi-asserted-by":"publisher","first-page":"649","DOI":"10.1001\/archpsyc.61.7.649","volume":"61","author":"TU Woo","year":"2004","unstructured":"Woo, T. U., Walsh, J. P. & Benes, F. M. Density of glutamic acid decarboxylase 67 messenger RNA-containing neurons that express the N-methyl-D-aspartate receptor subunit NR2A in the anterior cingulate cortex in schizophrenia and bipolar disorder. Arch. Gen. Psychiatry 61, 649\u2013657 (2004).","journal-title":"Arch. Gen. Psychiatry"},{"key":"660_CR32","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00418-018-1725-2","volume":"150","author":"FL Groeneweg","year":"2018","unstructured":"Groeneweg, F. L., Trattnig, C., Kuhse, J., Nawrotzki, R. A. & Kirsch, J. Gephyrin: a key regulatory protein of inhibitory synapses and beyond. Histochem. Cell Biol. 150, 489\u2013508 (2018).","journal-title":"Histochem. Cell Biol."},{"key":"660_CR33","doi-asserted-by":"publisher","unstructured":"Berdenis van Berlekom A. et al. Synapse pathology in schizophrenia: a meta-analysis of postsynaptic elements in postmortem brain studies. Schizophr Bull. pii: sbz060 2019. https:\/\/doi.org\/10.1093\/schbul\/sbz060.","DOI":"10.1093\/schbul\/sbz060"},{"key":"660_CR34","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1038\/nprot.2012.116","volume":"7","author":"Y Shi","year":"2012","unstructured":"Shi, Y., Kirwan, P. & Livesey, F. J. Directed differentiation of human pluripotent stem cells to cerebral cortex neurons and neural networks. Nat. Protoc. 7, 1836\u20131846 (2012).","journal-title":"Nat. Protoc."},{"key":"660_CR35","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.mcn.2016.01.003","volume":"73","author":"B Watmuff","year":"2016","unstructured":"Watmuff, B. et al. Disease signatures for schizophrenia and bipolar disorder using patient-derived induced pluripotent stem cells. Mol. Cell. Neurosci. 73, 96\u2013103 (2016).","journal-title":"Mol. Cell. Neurosci."},{"key":"660_CR36","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1016\/j.pharep.2014.04.011","volume":"66","author":"M Ma\u0107kowiak","year":"2014","unstructured":"Ma\u0107kowiak, M., Mordalska, P. & W\u0119dzony, K. Neuroligins, synapse balance and neuropsychiatric disorders. Pharmacol. Rep. 66, 830\u2013835 (2014).","journal-title":"Pharmacol. Rep."},{"key":"660_CR37","doi-asserted-by":"publisher","first-page":"26262","DOI":"10.1074\/jbc.M116.760017","volume":"291","author":"CS Sullivan","year":"2016","unstructured":"Sullivan, C. S., K\u00fcmper, M., Temple, B. S. & Maness, P. F. The neural cell adhesion molecule (NCAM) promotes clustering and activation of EphA3 receptors in GABAergic interneurons to induce ras homolog gene family, member A (RhoA)\/Rho-associated protein kinase (ROCK)-mediated growth cone collapse. J. Biol. Chem. 291, 26262\u201372. (2016).","journal-title":"J. Biol. Chem."},{"key":"660_CR38","doi-asserted-by":"crossref","unstructured":"Nguyen Q. A., Horn M. E., Nicoll R. A. Distinct roles for extracellular and intracellular domains in neuroligin function at inhibitory synapses. Elife. 5, e19236. (2016).","DOI":"10.7554\/eLife.19236"},{"key":"660_CR39","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1093\/schbul\/sbx093","volume":"44","author":"P Conus","year":"2018","unstructured":"Conus, P. et al. N-acetylcysteine in a double-blind randomized placebo-controlled trial: toward biomarker-guided treatment in early psychosis. Schizophr. Bull. 44, 317\u201327. (2018).","journal-title":"Schizophr. Bull."},{"key":"660_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.psychres.2019.03.018","volume":"275","author":"RR Girgis","year":"2019","unstructured":"Girgis, R. R. et al. Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: a pilot in vivo proton magnetic resonance spectroscopy study. Psychiatry Res. 275, 78\u201385 (2019).","journal-title":"Psychiatry Res."},{"key":"660_CR41","doi-asserted-by":"publisher","first-page":"1428","DOI":"10.1089\/ars.2012.4858","volume":"18","author":"A Kulak","year":"2013","unstructured":"Kulak, A. et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid. Redox Signal. 18, 1428\u20131443 (2013).","journal-title":"Antioxid. Redox Signal."},{"key":"660_CR42","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0266-8","volume":"8","author":"P Klauser","year":"2018","unstructured":"Klauser, P. et al. N-acetylcysteine add-on treatment leads to an improvement of fornix white matter integrity in early psychosis: a double-blind randomized placebo-controlled trial. Transl. Psychiatry 8, 220 (2018).","journal-title":"Transl. Psychiatry"},{"key":"660_CR43","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1093\/ijnp\/pyz022","volume":"22","author":"E Mullier","year":"2019","unstructured":"Mullier, E. et al. N-acetyl-cysteine supplementation improves functional connectivity within the cingulate cortex in early psychosis: a pilot study. Int. J. Neuropsychopharmacol. 22, 478\u201387. (2019).","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"660_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.mcn.2016.03.007","volume":"73","author":"R Karmacharya","year":"2016","unstructured":"Karmacharya, R. & Haggarty, S. J. Stem cell models of neuropsychiatric disorders. Mol. Cell. Neurosci. 73, 1\u20132 (2016).","journal-title":"Mol. Cell. Neurosci."},{"key":"660_CR45","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1038\/s41593-018-0334-7","volume":"22","author":"CM Sellgren","year":"2019","unstructured":"Sellgren, C. M. et al. Increased synapse elimination by microglia in schizophrenia patient-derived models of synaptic pruning. Nat. Neurosci. 22, 374\u201385. (2019).","journal-title":"Nat. Neurosci."},{"key":"660_CR46","doi-asserted-by":"publisher","DOI":"10.1038\/tp.2014.12","volume":"4","author":"HM Chen","year":"2014","unstructured":"Chen, H. M. et al. Transcripts involved in calcium signaling and telencephalic neuronal fate are altered in induced pluripotent stem cells from bipolar disorder patients. Transl. Psychiatry 4, e375 (2014).","journal-title":"Transl. Psychiatry"},{"key":"660_CR47","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1016\/j.mcn.2015.11.006","volume":"73","author":"KS O\u2019Shea","year":"2015","unstructured":"O\u2019Shea, K. S. & McInnis, M. G. Neurodevelopmental origins of bipolar disorder: iPSC models. Mol. Cell. Neurosci. 73, 63\u201383 (2015).","journal-title":"Mol. Cell. Neurosci."},{"key":"660_CR48","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-019-0517-3","volume":"9","author":"LM Grunwald","year":"2019","unstructured":"Grunwald, L. M. et al. Comparative characterization of human induced pluripotent stem cells (hiPSC) derived from patients with schizophrenia and autism. Transl. Psychiatry 9, 179 (2019).","journal-title":"Transl. Psychiatry"},{"key":"660_CR49","doi-asserted-by":"publisher","first-page":"471","DOI":"10.2217\/pgs-2016-0187","volume":"18","author":"B Watmuff","year":"2017","unstructured":"Watmuff, B., Liu, B. & Karmacharya, R. Stem cell-derived neurons in the development of targeted treatment for schizophrenia and bipolar disorder. Pharmacogenomics 18, 471\u2013479 (2017).","journal-title":"Pharmacogenomics"},{"key":"660_CR50","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.mcn.2015.11.009","volume":"73","author":"M Lin","year":"2015","unstructured":"Lin, M., Lachman, H. M. & Zheng, D. Transcriptomics analysis of iPSC-derived neurons and modeling of neuropsychiatric disorders. Mol. Cell. Neurosci. 73, 32\u201342 (2015).","journal-title":"Mol. Cell. Neurosci."},{"key":"660_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41398-018-0284-6","volume":"8","author":"DL McPhie","year":"2018","unstructured":"McPhie, D. L. et al. Oligodendrocyte differentiation of induced pluripotent stem cells derived from subjects with schizophrenias implicate abnormalities in development. Transl. Psychiatry 8, 230 (2018).","journal-title":"Transl. Psychiatry"},{"key":"660_CR52","doi-asserted-by":"publisher","unstructured":"Ni P. et al. iPSC-derived homogeneous populations of developing schizophrenia cortical interneurons have compromised mitochondrial function. Molecular psychiatry. https:\/\/doi.org\/10.1038\/s41380-019-0423-3 (2019).","DOI":"10.1038\/s41380-019-0423-3"},{"key":"660_CR53","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1176\/appi.ajp.2014.14040435","volume":"172","author":"J Arnedo","year":"2015","unstructured":"Arnedo, J. et al. Uncovering the hidden risk architecture of the schizophrenias: confirmation in three independent genome-wide association studies. Am. J. Psychiatry 172, 139\u2013153 (2015).","journal-title":"Am. J. Psychiatry"},{"key":"660_CR54","doi-asserted-by":"publisher","first-page":"20120292","DOI":"10.1098\/rstb.2012.0292","volume":"368","author":"A Watanabe","year":"2013","unstructured":"Watanabe, A., Yamada, Y. & Yamanaka, S. Epigenetic regulation in pluripotent stem cells: a key to breaking the epigenetic barrier. Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci. 368, 20120292 (2013).","journal-title":"Philos. Trans. R. Soc. Lond. Ser. B Biol. Sci."}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0660-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0660-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0660-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,16]],"date-time":"2022-12-16T15:58:36Z","timestamp":1671206316000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41398-019-0660-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,28]]},"references-count":54,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["660"],"URL":"https:\/\/doi.org\/10.1038\/s41398-019-0660-x","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,28]]},"assertion":[{"value":"8 August 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 September 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 October 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"321"}}